MentionFox
Home › Stakes › Contineum Therapeutics, Inc.
5%+ stakes · Schedule 13D and 13G

Contineum Therapeutics, Inc.: 5%+ holders

Who has reported owning 5% or more of Contineum Therapeutics, Inc., from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more4
Filings14
Latest filing2026-08-14

Contineum Therapeutics, Inc. has 14 Schedule 13D or 13G filings on record since 2025-07-25. 4 holders' latest filing reports 5% or more of class a common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
Janus Henderson Group Plc7.9%2,448,979SCHEDULE 13G, 2026-02-172025-12-31
Balyasny Asset Management L.P.7.14%2,335,550SCHEDULE 13G/A, 2026-08-142026-06-30
BlackRock, Inc.6.3%2,049,493SCHEDULE 13G, 2026-07-272026-06-30
Franklin Resources, Inc.6.2%1,879,367SCHEDULE 13G/A, 2026-01-292025-12-31
RA Capital Management, L.P.4%1,296,012SCHEDULE 13G/A, 2026-05-152026-03-31
Perceptive Advisors LLC3.2%699,486SCHEDULE 13G/A, 2025-08-142025-06-30
Millennium Management LLC2.8%931,709SCHEDULE 13G/A, 2026-07-172026-06-30

Timeline

FiledHolderPercentFiling
2025-07-25RA Capital Management, L.P.9.9%SCHEDULE 13G
2025-08-05Franklin Resources, Inc.8.9%SCHEDULE 13G/A
2025-08-14Perceptive Advisors LLC3.2%SCHEDULE 13G/A
2025-11-04Franklin Resources, Inc.7.7%SCHEDULE 13G/A
2026-01-29Franklin Resources, Inc.6.2%SCHEDULE 13G/A
2026-02-17Balyasny Asset Management L.P.7.6%SCHEDULE 13G
2026-02-17Janus Henderson Group Plc7.9%SCHEDULE 13G
2026-02-17RA Capital Management, L.P.7.2%SCHEDULE 13G/A
2026-04-17Millennium Management LLC5.1%SCHEDULE 13G
2026-05-15Balyasny Asset Management L.P.7.4%SCHEDULE 13G
2026-05-15RA Capital Management, L.P.4%SCHEDULE 13G/A
2026-07-17Millennium Management LLC2.8%SCHEDULE 13G/A
2026-07-27BlackRock, Inc.6.3%SCHEDULE 13G
2026-08-14Balyasny Asset Management L.P.7.14%SCHEDULE 13G/A

Tools for this story

Each opens in a new tab, filled in for Contineum Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/contineum-therapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Contineum Therapeutics, Inc. 5%+ holders: 4 at 5% or more, largest Janus Henderson Group Plc 7.9%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/contineum-therapeutics